Fusen Pharmaceutical Company Limited (1652.HK)
HKD 0.3
(13.46%)
HKD 0.3
(13.46%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 18.93 Million CNY | -11.79% |
| 2022 | 49.89 Million CNY | -42.54% |
| 2021 | 86.83 Million CNY | -30.9% |
| 2020 | 110.29 Million CNY | 66.78% |
| 2019 | 75.35 Million CNY | -47.94% |
| 2018 | 144.74 Million CNY | -10.17% |
| 2017 | 138.37 Million CNY | -5.0% |
| 2016 | 169.61 Million CNY | 47.85% |
| 2015 | 101.91 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -9.76 Million CNY | 0.0% |
| 2024 Q1 | -9.76 Million CNY | -776.45% |
| 2023 Q1 | 25.89 Million CNY | -2.46% |
| 2023 Q4 | -1.11 Million CNY | 0.0% |
| 2023 FY | - CNY | -11.79% |
| 2023 Q2 | 25.89 Million CNY | 0.0% |
| 2023 Q3 | -1.11 Million CNY | -104.3% |
| 2022 Q1 | 9.61 Million CNY | -25.46% |
| 2022 FY | - CNY | -42.54% |
| 2022 Q3 | 26.54 Million CNY | 175.94% |
| 2022 Q2 | 9.61 Million CNY | 0.0% |
| 2022 Q4 | 26.54 Million CNY | 0.0% |
| 2021 Q2 | 28.76 Million CNY | 0.0% |
| 2021 Q3 | 12.9 Million CNY | -55.14% |
| 2021 FY | - CNY | -30.9% |
| 2021 Q4 | 12.9 Million CNY | 0.0% |
| 2021 Q1 | 28.76 Million CNY | -2.58% |
| 2020 Q4 | 29.52 Million CNY | 0.0% |
| 2020 Q2 | 19.54 Million CNY | 0.0% |
| 2020 FY | - CNY | 66.78% |
| 2020 Q1 | 19.54 Million CNY | 71.0% |
| 2020 Q3 | 29.52 Million CNY | 51.12% |
| 2019 FY | - CNY | -47.94% |
| 2019 Q4 | 11.42 Million CNY | 0.0% |
| 2019 Q3 | 11.42 Million CNY | -43.63% |
| 2019 Q2 | 20.27 Million CNY | 0.0% |
| 2019 Q1 | 20.27 Million CNY | -29.78% |
| 2018 Q3 | 28.87 Million CNY | -30.4% |
| 2018 Q4 | 28.87 Million CNY | 0.0% |
| 2018 Q1 | 41.48 Million CNY | 7.96% |
| 2018 Q2 | 41.48 Million CNY | 0.0% |
| 2018 FY | - CNY | -10.17% |
| 2017 Q1 | 37.05 Million CNY | 39.61% |
| 2017 FY | - CNY | -5.0% |
| 2017 Q4 | 38.42 Million CNY | 0.0% |
| 2017 Q2 | 37.05 Million CNY | 0.0% |
| 2016 Q1 | 42.12 Million CNY | 0.0% |
| 2016 Q4 | 26.54 Million CNY | 0.0% |
| 2016 FY | - CNY | 47.85% |
| 2016 Q2 | 42.12 Million CNY | 0.0% |
| 2015 FY | - CNY | 0.0% |
| 2015 Q3 | 28.39 Million CNY | 0.0% |
| 2015 Q4 | 42.12 Million CNY | 48.37% |
| 2015 Q2 | 28.39 Million CNY | 0.0% |
| 2015 Q1 | 28.39 Million CNY | 0.0% |
| 2014 Q4 | 28.39 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 87.412% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 99.362% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 114.618% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 83.363% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 137.693% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 82.76% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 95.475% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | 75.294% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 172.349% |
| SSY Group Limited | 2.11 Billion HKD | 99.105% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 90.737% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 95.596% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 99.877% |